Mechano growth factor pegylated (PEG-MGF)
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Research / no approved-treatment claim
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Purported uses, not established benefits
Proponents claim PEG-MGF may support muscle repair and growth after exercise or injury.
The review reports no peer-reviewed human studies for PEG-MGF. Findings about related growth-factor signaling do not establish its clinical benefit.
Evidence and source limits
Compounded drugs containing Mechano Growth Factor Pegylated (PEG-MGF) may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified any human exposure data on drug products containing PEG-MGF administered via any route of administration. FDA lacks important information regarding any safety issues raised by PEG-MGF, including whether it would cause harm if administered to humans.
This entry records a regulator safety assessment, not a treatment benefit or a clinical recommendation. A research-purpose-only label does not establish safety, FDA approval or permission to use a substance in people. No dosing, supplier or administration guidance is provided.
Original source: Mechano growth factor pegylated (PEG-MGF) ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.